PDCD1 and non-small cell lung carcinoma: Pembrolizumab, another PD-1 inhibitor, achieved a 39% objective response rate in patients with locally advanced or metastatic NSCLC, with a PD-L1 tumor proportion score ≥50% (Mok et al., 2019).